AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02308501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lastacaft ®
Study NCT02308501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tears Naturale ® (Placebo)
Study NCT01190033 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurotome OFF
Description: In this intervention the neurotome will be unconnected.
Study NCT01190033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neurolysis
Description: In this procedure the neurotome will be connected
Study NCT00068666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00068666 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04033991 — intervention group
Intervention type: DRUG
Intervention: Sunitinib
Description: Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
Study NCT04033991 — intervention group
Intervention type: DRUG
Intervention: Axitinib
Description: Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
Study NCT00967863 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy
Study NCT00967863 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Patients undergo radiotherapy
Study NCT01324466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NB-001
Description: Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
Study NCT01324466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
Study NCT03765359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metforminhydrochloride
Description: metformin 500 mg tablets and insulin
Study NCT01470378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thigh Surgery
Description: Circumferential thigh surgery post bariatric surgery
Study NCT00770185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00770185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT02410161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-linolenic acid-rich supplement
Description: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
Study NCT04501458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of youth, community health assistants and community health workers.
Description: Training of youth, community health assistants, and community health workers in the screening, detection, contact tracing, prevention, and management of COVID-19 with concurrent maintenance of essential health services.
Study NCT04501458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training clinicians in basic critical care and the management of severe COVID-19 cases
Description: Training clinicians in basic critical care and the management of severe COVID-19 cases with concurrent maintenance of essential health services.
Study NCT02327910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOF unit TcPCO2 group
Description: The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
Study NCT03765359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets mimic metformin 500 mg tablets and insulin
Study NCT00666978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Study NCT02327910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOF group
Description: The patients of T group were extubated when TOF ratio greater than 0.9.
Study NCT01198925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin continuous infusion
Description: piperacillin continuous infusion
Study NCT01198925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: piperacillin extended infusion
Description: piperacillin extended infusion
Study NCT00632528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA
Description: Administration of MEOPA gaz during postoperative physical therapy
Study NCT00632528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medicinal air
Description: Administration of medical air during postoperative physical therapy
Study NCT04635787 — intervention group
Intervention type: DEVICE
Intervention: ANNE One
Description: Wireless vital sign monitoring device
Study NCT00131911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: 400 mg given orally
Study NCT01913964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Study NCT01913964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (sugar pill)
Study NCT02877953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the prevention of complications post-TIPS
Description: Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
Study NCT03519581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse Laser Treatment
Description: Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. Application of micropulse laser on retinal surface will occur using TxCell Scanning Delivery System in a 7 x 7 grid to surround the fovea.
Study NCT03519581 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment
Description: Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. No actual laser treatment will occur.
Study NCT03666065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart insulin
Description: Standard insulin
Study NCT03666065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart insulin
Description: Standard insulin
Study NCT04219709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein.
Study NCT04219709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard carbohydrate diet
Description: All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein.
Study NCT04179994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak extract-containing toothpaste
Description: Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
Study NCT04179994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrates-containing toothpaste
Description: Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
Study NCT04179994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
Study NCT00401921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: 100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
Study NCT00401921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
Study NCT04676828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-photon-emission CT scan
Description: SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung
Study NCT00620958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual cognitive behavioral therapy (ICBT)
Description: ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
Study NCT00620958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)
Description: Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
Study NCT00620958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)
Description: Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
Study NCT00496990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced care
Description: this group received counseling, contingency management and methadone or detoxification
Study NCT00496990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: this group receives the opportunity to participate in a support group
Study NCT01472432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
Study NCT01472432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: 50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
Study NCT01275664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy
Description: Ancillary studies
Study NCT00666978 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation intervention
Study NCT00666978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Study NCT00666978 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00666978 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: gene expression analysis
Study NCT00666978 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Study NCT00666978 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: polymerase chain reaction
Study NCT00666978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Study NCT00666978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: counseling intervention
Study NCT00666978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study NCT00666978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: educational intervention
Study NCT00666978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study NCT00666978 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: psychosocial assessment and care
Study NCT02884466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation intervention
Description: Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
Study NCT02884466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary rehabilitation intervention
Description: Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
Study NCT01203462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic strain of Bifidobacterium
Description: 4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
Study NCT01203462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Bifidobacterium
Description: 4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
Study NCT04442620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity and Mediterranean Diet (PA-MD)
Description: Physical Activity plus caloric restricted Mediterranean diet
Study NCT04442620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High meal frequency of Mediterranean Diet (HMF-MD)
Description: High meal frequency of unaltered Mediterranean diet
Study NCT04442620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet (CD)
Description: Control Diet
Study NCT00388362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
Study NCT00520689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Hydrogel Contact Lens
Description: use of lens over 2 days
Study NCT01477632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Description: A single oral dose of 2 tablets under fasting conditions
Study NCT01477632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
Description: A single oral dose of 2 tablets under fasting conditions
Study NCT01477632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
Description: A single oral dose of 1 tablet under fasting conditions
Study NCT01571674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation + Exercise Group
Description: First 2 sessions~* High-velocity, low-amplitude manipulations to the thoracic spine.~* Low-velocity mid to end-range mobilizations to the cervical spine.~* Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program
Study NCT01571674 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group
Description: First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program
Study NCT01571674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program
Study NCT01469923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD2820
Description: Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
Study NCT01469923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
Study NCT04507308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session sleep intervention drawn from principles of the TranS-C youth protocol
Description: We are providing participants psychoeducation on sleep and will be going over several handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth) to improve sleep.
Study NCT01099826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored counseling
Description: education tailored to baseline beliefs by trained counselor over phone
Study NCT01099826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: motivational interview by trained MI counselors by phone
Study NCT02847611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamometer LABIN
Description: LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
Study NCT00635531 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
Study NCT00635531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam XR
Description: Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
Study NCT02996305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101 Regimen 1
Study NCT02996305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101 regimen 2
Study NCT02996305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00388362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
Study NCT01448837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost/Timolol, 24-hour intraocular pressure monitoring
Description: Administered once in the evening
Study NCT01448837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost, 24-hour intraocular pressure monitoring
Description: assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
Study NCT00209027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI scanning during behavioral reward task
Study NCT00209027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 30 mg by mouth once daily
Study NCT02919956 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
Study NCT01225263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin, 20 mg, twice daily for 6 months
Study NCT01225263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D3, 1000 IU, twice daily for 6 months
Study NCT01275664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Given IV and PO
Study NCT01275664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP
Study NCT01275664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IP
Study NCT01275664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO